Kymera Therapeutics shares surged Thursday after the biotechnology company said it completed enrollment in a mid-stage trial of its atopic dermatitis treatment candidate ahead of schedule, ...
Investor's Business Daily on MSN
Is Kymera Therapeutics the next big rival to Regeneron and Sanofi?
Kymera Therapeutics shares catapulted Thursday after the company wrapped enrollment in an eczema study six months ahead of expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results